You are here

Home » Content

Sürekli Ayaktan Periton Diyalizi Hastalarında Metabolik Sendrom Sıklığı ve Metabolik Sendrom Gelişiminin Diyaliz Süresi ile İlişkisi

The Frequency Of Metabolic Syndrome in Patients on Continuous Ambulatory Peritoneal Dialysis and the Association of Developing Metabolic Syndrome Wıth Dialysis Duration

Journal Name:

  • Türk Nefroloji, Diyaliz ve Transplantasyon Dergisi

Publication Year:

  • 2011
DOI: 
10.5262/tndt.2011.1002.09

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
OBJECTIV E: To evaluate the characteristics of patients with metabolic syndrome, and the association of developing MS with peritoneal dialysis duration among patients undergoing continuous ambulatory peritoneal dialysis. MA TERIAL and M ETHODS: Fifty-eight nondiabetic CAPD patients were evaluated. Biochemical parameters, blood pressure, length, weight, waist circumference, and body mass indexes were recorded. MS was determined using NCP-ATP III criteria. The patients were divided into 3 groups according to dialysis duration (Group 1: ≤60 months, Group 2: 61-120 months, Group 3: ≥121 months) and the frequency of MS was compared. RESUL TS: Twenty-four of 58 patients were male, and MS was present in 22 (37.9%) patients. 14 (82.4%) of 22 patients with MS were female, (p=0.544). There was a statistically significant difference between patients with and without MS regarding age, BMI, waist circumference, PD duration, and triglyceride levels (p<0.05). 55% (n=32) of the patients were in group 1, 34.5% (n=20) in group 2, and 10.5% (n=6) in group 3 (p=0.092). The frequency of MS decreased with prolongation of dialysis duration (50% in group 1, 20% in group 2, and 33,3% in group 3) (p<0.001). CONCLU SION: The frequency of MS among our CAPD patients was 37.9% and it decreased with prolongation of dialysis duration. This result may suggest that alterations in metabolic state, and abandoning glucose-based PD solutions may improve MS criteria.
Bookmark/Search this post with
Abstract (Original Language): 
AMA Ç: Sürekli ayaktan periton diyaliz (SAPD) tedavisi gören hastalarımızda metabolik sendromlu (MS) hastaların özelliklerini ve MS gelişimi ile SAPD süresi arasındaki ilişkiyi araştırmayı amaçladık. GEREÇ ve yönte mler : En az 1 yıldır SAPD tedavisi alan 58 nondiyabetik hasta incelendi. Tüm hastaların biyokimyasal göstergeleri, kan basınçları, boy, kilo, bel çevreleri ve vücut kütle indeksleri kaydedildi. MS, Ulusal Kolesterol Eğitim Programı (Adult Treatment Panel III) ölçütlerine göre tanımlandı. Hastalar PD sürelerine göre 3 gruba ayrıldı (Grup 1: ≤ 60 ay, Grup 2: 61-120 ay ve Grup 3: ≥ 121 ay) ve MS gelişim sıklığı karşılaştırıldı. BUL GULA R: 58 hastanın 24’ü erkek, 34’ü kadındı. Hastaların 22 (%37,9)’sinde MS saptanırken, 36 (%62,1)’sında saptanmadı. MS saptanan 22 hastanın 14’ü (%82,4) kadın, 8’i (%17,6) erkeklerden oluşmakta idi (p=0,544). MS olan grupla olmayan grup karşılaştırıldığında yaş, VKİ, bel çevresi, PD süresi ve trigliserid düzeyleri arasında fark saptanırken (p<0,05), diğer göstergelerde fark saptanmadı. Hastaların %55’i (n=32) grup 1’i, %34,5’i (n=20) grup 2’yi ve %10,5’i (n=6) grup 3’ü oluşturdu. Grupları karşılaştırdığımızda PD süresi ilerledikçe MS görülme sıklığının azaldığını saptadık (grup 1 %50, grup 2 %20 ve grup 3 %33,3) (p<0,001). SONU Ç: SAPD hastalarımızda MS sıklığının %37,9 olduğunu ve PD süresi uzadıkça hastalarda metabolik sendrom sıklığının azaldığını saptadık. Bu sonuç hastaların metabolik tablosundaki değişikliklerin ve ilerleyen süreçte glikoz bazlı solüsyonların terk edilmesinin MS göstergelerinde anlamlı düzelme sağladığını düşündürmektedir.
FULL TEXT (PDF): 
PDF icon arastrmx_172977_20_pp_162-168.pdf
  • 2
162-168
  • Turkish

REFERENCES

References: 

1. Sitter T, Sauter M: Impact of glucose in peritoneal dialysis: Saint or
sinner. Perit Dial Int 2005; 25: 415-425
2. Holmes CJ, Shockley TR: Strategies to reduce glucose exposure in
peritoneal dialysis patients. Perit Dial Int 2000; 20: 37- 41
3. Heimbürger O, Waniewski J, Werynski A, Lindholm B: A quantitative
description of solute and fluid transport during peritoneal dialysis.
Kidney Int 1992; 41: 1320-1332
4. Bergström J, Fürst P, Alvestrand A, Lindholm B: Protein and energy
intake, nitrogen balance and nitrogen losses in patients treated with
continuous ambulatory peritoneal dialysis. Kidney Int 1993; 44:
1048-1057
5. Grostein GP, Blumenkrantz MJ, Kopple JD, Moran JK, Coburn
JW: Glucose absorption during continuous ambulatory peritoneal
dialysis. Kidney Int 1981; 19: 564-567
Kayabaşı H ve ark : Periton Diyalizi Hastalarında Metabolik Sendrom
172 Turk Neph Dial Transpl 2011; 20 (2): 168-172
Türk N efroloji D iyaliz ve Transplantasyon D ergisi
Turkish Nephrology, Dialysis and Transplantation Journal
6. Holmes C, Mujais S: Glucose sparing in peritoneal dialysis:
Implications and metrics. Kidney Int 2006; 70: 104-109
7. Luke RG: Chronic renal failure-a vasculopathic state. N Engl J Med
1998; 339: 841-843
8. Locatelli F, Marcelli D, Conte F, D’Amico M, Del Vecchio L,
Limido A, Malberti F, Spotti D: Cardiovascular disease in chronic
renal failure: The challenge continues. Nephrol Dial Transplant
2000; 15: 69-80
9. Levey AS, Beto JA, Coronado BE, Eknoyan G, Foley RN, Kasiske
BL, Klag MJ, Mailloux LU, Manske CL, Meyer KB, Parfrey PS,
Pfeffer MA, Wenger NK, Wilson PWF, Wright JT Jr: Controlling
the epidemic of cardiovascular disease in chronic renal disease:
What do we know? What do we need to learn? Where do we go
from here? Am J Kidney Dis 1998; 32: 853-906
10. Brunner FP, Selwood NH: Profile of patients on RRT in Europe
and death rates due to major causes of death groups. The EDTA
Registration Committee. Kidney Int Suppl 1992; 38: 4-15
11. Serdengeçti K, Süleymanlar G, Altıparmak MR, Seyahi N,
TND Registry Grubu: Türk Nefroloji Derneği Kayıt Sistemi
Raporları-2009
12. Park SH, Lindholm B: Definition of metabolic syndrome in
peritoneal dialysis. Perit Dial Int 2009; 2: 137-144
13. Johnson DW, Armstrong K, Campbell SB, Mudge DW, Hawley
CM, Coombes JS, Prins JB, Isbel NM: Metabolic syndrome in
severe chronic kidney disease: Prevalence, predictors, prognostic
significance and effects of risk factor modification. Nephrology
(Carlton) 2007; 12: 391-398
14. Laaksonen DE, Lakka HM, Niskanen LK, Kaplan GA, Salonen
JT, Lakka TA: Metabolic syndrome and development of diabetes
mellitus: Application and validation of recently suggested
definitions of the metabolic syndrome in a prospective cohort study.
Am J Epidemiol 2002; 156: 1070-1077
15. Ninomiya JK, L’Italien G, Criqui MH, Whyte JL, Gamst A,
Chen RS: Association of the metabolic syndrome with history of
myocardial infarction and stroke in the Third National Health and
Nutrition Examination Survey. Circulation 2004; 109: 42-46
16. Kurella M, Lo JC, Chertow GM: Metabolic syndrome and the risk
for chronic kidney disease among nondiabetic adults. J Am Soc
Nephrol 2005; 16: 2134-2140
17. Tanaka H, Shiohira Y, Uezu Y, Higa A, Iseki K: Metabolic syndrome
and chronic kidney disease in Okinawa, Japan. Kidney Int 2006; 69:
369-374
18. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo
E, Tuomilehto J, Salonen JT: The metabolic syndrome and total and
cardiovascular disease mortality in middleaged men. JAMA 2002;
288: 2709-2716
19. Gallieni M, Musetti C, Granata A, Olivi L, Bertoli S: Metabolic
consequences of peritoneal dialysis treatment. Panminerva Med
2009; 51(3): 175-185
20. Kobayashi S, Maejima S, Ikeda T, Nagase M: Impact of dialysis
therapy on insulin resistance in end-stage renal. disease: Comparison
of haemodialysis and continuous ambulatory peritoneal dialysis.
Nephrol Dial Transplant 2000; 15: 65-70
21. Canbakan M, Sahin GM: Icodextrine and insulin resistance in
continuous ambulatory peritoneal dialysis patients. Ren Fail 2007;
29: 289-293
22. Takeguchi F, Nakayama M, Nakao T: Effects of icodextrin on insulin
resistance and adipocytokine profiles in patients on peritoneal
dialysis. Ther Apher Dial 2008; 12: 243-249
23. Chen HY, Kao TW, Huang JW, Chu TS, Wu KD: Correlation of
metabolic syndrome with residual renal function, solute transport
rate and peritoneal solute clearance in chronic peritoneal dialysis
patients. Blood Purif 2008; 26: 138-144
24. Jiang N, Qian J, Lin A, Lindholm B, Axelsson J, Yao Q: Initiation
of glucose-based peritoneal dialysis is associated with increased
prevalence of metabolic syndrome in non-diabetic patients with
end-stage renal disease. Blood Purif 2008; 26: 423-428
25. Johansen KL, Young B, Kaysen GA, Chertow GM: Association of
body size with outcomes among patients beginning dialysis. Am J
Clin Nutr 2004; 80: 324-332
26. Aslam N, Bernardini J, Fried L, Piraino B: Large body mass index
does not predict short-term survival in peritoneal dialysis patients.
Perit Dial Int 2002; 22: 191-196
27. McDonald SP, Collins JF, Johnson DW: Obesity is associated with
worse peritoneal dialysis outcomes in the Australia and New Zealand
patient populations. J Am Soc Nephrol 2003; 14:2894-2901
28. Diaz-Buxo JA, Burgess WP: Is weight gain inevitable in most chronic
peritoneal dialysis patients? Adv Perit Dial 1992; 8: 334-339

Thank you for copying data from http://www.arastirmax.com